These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 29221430)
1. The study of intravitreal drug pharmacokinetics: does it matter? and if so, how? Stewart MW Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):5-7. PubMed ID: 29221430 [No Abstract] [Full Text] [Related]
2. Intravitreal clearance and volume of distribution of compounds in rabbits: In silico prediction and pharmacokinetic simulations for drug development. del Amo EM; Vellonen KS; Kidron H; Urtti A Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):215-26. PubMed ID: 25603198 [TBL] [Abstract][Full Text] [Related]
3. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration. Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Schwab D; Mazer NA Mol Pharm; 2016 Sep; 13(9):2941-50. PubMed ID: 26726925 [TBL] [Abstract][Full Text] [Related]
4. Importance of Drug Pharmacokinetics at the Site of Action. Rizk ML; Zou L; Savic RM; Dooley KE Clin Transl Sci; 2017 May; 10(3):133-142. PubMed ID: 28160433 [No Abstract] [Full Text] [Related]
5. Routes for Drug Delivery to the Eye and Retina: Intravitreal Injections. Meyer CH; Krohne TU; Charbel Issa P; Liu Z; Holz FG Dev Ophthalmol; 2016; 55():63-70. PubMed ID: 26501462 [TBL] [Abstract][Full Text] [Related]
6. Primer on clinical pharmacokinetics. Bauer LA Am J Hosp Pharm; 1983 Oct; 40(10):1637-41. PubMed ID: 6638025 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema. Zhang Y; Yao Z; Kaila N; Kuebler P; Visich J; Maia M; Tuomi L; Ehrlich JS; Rubio RG; Campochiaro PA Ophthalmology; 2014 Nov; 121(11):2237-46. PubMed ID: 25001159 [TBL] [Abstract][Full Text] [Related]
8. ICH discussion on pharmacokinetics and toxicokinetics and contributors. Ohno Y Drug Metab Pharmacokinet; 2013; 28(5):379-82. PubMed ID: 24162438 [No Abstract] [Full Text] [Related]
9. Recent developments in ocular drug delivery. Chen H J Drug Target; 2015; 23(7-8):597-604. PubMed ID: 26453157 [TBL] [Abstract][Full Text] [Related]
11. High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States. Erie JC; Barkmeier AJ; Hodge DO; Mahr MA Ophthalmology; 2016 Jun; 123(6):1257-62. PubMed ID: 26976701 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes. Edington M; Connolly J; Chong NV Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1217-1224. PubMed ID: 29134820 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant. Park J; Bungay PM; Lutz RJ; Augsburger JJ; Millard RW; Sinha Roy A; Banerjee RK J Control Release; 2005 Jul; 105(3):279-95. PubMed ID: 15896868 [TBL] [Abstract][Full Text] [Related]
19. Optimizing drug development and use in patients with kidney disease. Nolin TD; Arya V; Sitar DS; Pfister M J Clin Pharmacol; 2011 May; 51(5):628-30. PubMed ID: 21525394 [No Abstract] [Full Text] [Related]
20. Arteriosclerotic Changes after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Drugs in Patients with Exudative Age-Related Macular Degeneration. Shiba T; Takahashi M; Yoshida I; Taniguchi H; Matsumoto T; Hori Y Ophthalmologica; 2016; 235(4):225-32. PubMed ID: 27082736 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]